BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN

Their core work

The Bernhard-Nocht Institute for Tropical Medicine (BNI) is Germany's largest research centre for tropical and emerging infectious diseases, based in Hamburg. They specialize in understanding the biology, pathology, and immunology of dangerous pathogens — particularly filoviruses (Ebola), arboviruses (Zika, Yellow Fever), and malaria parasites. Their practical contributions include developing diagnostics, vaccines, and containment strategies for outbreaks, as well as maintaining high-biosafety-level laboratory infrastructure for work with highly pathogenic agents. BNI also serves as a reference laboratory and virus archive contributor, making pathogen samples and derived products available to the wider research community.

What they specialise in

How they've shifted over time

BNI's early H2020 work (2014–2017) was dominated by the Ebola crisis response — five of their first seven projects dealt directly with Ebola vaccines, diagnostics, clinical management, and pathophysiology, reflecting the urgency of the 2014 West Africa outbreak. From 2019 onward, their focus broadened significantly: they moved into vaccination strategies for aging populations (ISOLDA), research infrastructure sustainability (ERINHA-Advance), and secured a prestigious ERC Advanced Grant for malaria research (MALART). This shift suggests a maturation from outbreak-reactive work toward longer-term, fundamental infectious disease research with stronger institutional funding.

BNI is moving from crisis-driven filovirus work toward fundamental parasitology and broader vaccine platforms for aging populations, suggesting future partnerships should target long-term immunology and drug resistance research.

How they like to work

BNI primarily operates as a specialist partner within large international consortia — 10 of 13 projects are as participant, often in groups spanning dozens of countries. Their three coordinated projects (EVIDENT, EBOPATH, MALART) are notably different in character: smaller, more focused efforts where BNI leads the science directly. With 200 unique partners across 47 countries, they are a highly networked institute that brings deep pathogen expertise into large multi-partner frameworks rather than building their own mega-consortia.

BNI has collaborated with 200 unique partners across 47 countries, reflecting the inherently global nature of tropical disease research. Their network spans well beyond Europe into endemic regions in Africa, Asia, and Latin America, making them a bridge between European research funding and global health field work.

What sets them apart

BNI is one of very few European institutions that combines BSL-4 high-containment laboratory capacity with deep expertise in tropical pathogens and a track record in both outbreak response and fundamental research. Unlike university departments that may study infectious disease theoretically, BNI works directly with live dangerous pathogens — Ebola, Zika, MERS-CoV, malaria — which requires specialized infrastructure that few partners can offer. Their ERC Advanced Grant for malaria artemisinin resistance signals scientific leadership, not just service provision.

Highlights from their portfolio

• MALART
  Their largest project (EUR 2.4M) and an ERC Advanced Grant — a mark of individual scientific excellence — investigating artemisinin resistance in malaria, a critical global health threat.
• EVIDENT
  Coordinated by BNI during the 2014 Ebola crisis to identify correlates of protection and clinical management strategies, demonstrating their rapid-response capability.
• EVA-GLOBAL
  Part of the European Virus Archive network providing reference virus collections and gold-standard products to researchers worldwide — a critical infrastructure role.